Contract Development Services

What do trends in small molecule drugs mean for contract manufacturers?

Sitting Down With... Ian Muir, Managing Director, Aesica, UK.

What can we learn about outsourcing trends from the last 40 years?

We forge ahead to celebrate the fantastic individuals involved in bettering the pharma industry.

The industry is shifting towards biopharmaceuticals, but there is still demand for synthetic APIs.

Small molecule APIs have been a strong focus throughout Bernhard Paul's career.

Today, the majority of the contract manufacturing market is made up of small molecules.

Outsourced manufacturing is set to grow by 6.6 percent over the next four years.

Mark Paxton was appointed CEO of Rx-360 in 2015. Here, he discusses the journey so far

Martin Van Trieste tells the emotional story behind the creation of Rx-360